Wells Fargo & Company Regulus Therapeutics Inc. Call Options Transaction History
Wells Fargo & Company
- $407 Billion
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding RGLS
# of Institutions
69Shares Held
53MCall Options Held
155KPut Options Held
34.2K-
Federated Hermes, Inc. Pittsburgh, PA12.9MShares$19.2 Million0.06% of portfolio
-
Ra Capital Management, L.P. Boston, MA6.25MShares$9.31 Million0.17% of portfolio
-
Vivo Capital, LLC Palo Alto, CA5MShares$7.45 Million1.32% of portfolio
-
Octagon Capital Advisors LP New York, NY4.26MShares$6.35 Million1.76% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.05MShares$6.04 Million0.0% of portfolio
About Regulus Therapeutics Inc.
- Ticker RGLS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 14,634,400
- Market Cap $21.8M
- Description
- Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-thre...